Literature DB >> 27650643

The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.

M Chakhtoura1, W D Leslie2, M McClung3, A M Cheung4, G El-Hajj Fuleihan5.   

Abstract

We describe our approach to develop FRAX-based osteoporosis treatment guidelines in Lebanon, a country with low-moderate fracture rates. A hybrid assessment algorithm that combines a fixed 10 % intervention threshold until age 70 years, and an age-dependent threshold thereafter, was deemed most suitable.
INTRODUCTION: The FRAX risk calculator is used to guide intervention thresholds in several national osteoporosis guidelines. This study aimed to describe the approach in developing FRAX-based osteoporosis treatment guidelines in Lebanon, a country with relatively low fracture rates.
METHODS: We reassessed previous national guidelines combined with an evaluation of age-dependent and fixed FRAX-based intervention threshold models used in the UK, the USA, and Canada. We took into consideration the risk for major osteoporotic fractures (MOF) and the proportions of subjects considered for therapy using such thresholds, before finalizing a model for Lebanon.
RESULTS: The new Lebanese guidelines retained the recommendation to treat individuals with fragility fracture at the hip or spine. A femoral neck T-score ≤-2.5 in subjects without fractures was dropped, since it would imply consideration of therapy for individuals with a 10-year risk for MOF of <10 %, up to age 75 years in women. After considering the impact of both age-dependent and fixed intervention thresholds, we chose a new hybrid algorithm, combining a fixed 10 % treatment threshold until age 70 years and an age-dependent threshold thereafter.
CONCLUSION: The Lebanese FRAX-based hybrid model takes into consideration the risk for MOF and the proportions of subjects considered for treatment. This model avoids consideration of drug therapy in a large proportion of younger subjects at low risk for fracture and targets high risk elderly individuals. It was deemed most suitable for Lebanon and may be an option for other countries with relatively low fracture rates.

Entities:  

Keywords:  Age dependent intervention threshold; FRAX; Fixed intervention threshold; Guidelines; Osteoporosis

Mesh:

Substances:

Year:  2016        PMID: 27650643     DOI: 10.1007/s00198-016-3766-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  49 in total

1.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

2.  Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.

Authors:  Silvia Rabar; Martin Harker; Norma O'Flynn; Anthony S Wierzbicki
Journal:  BMJ       Date:  2014-07-17

3.  Cost-effective osteoporosis treatment thresholds in Greece.

Authors:  P Makras; K Athanasakis; N Boubouchairopoulou; S Rizou; A D Anastasilakis; J Kyriopoulos; G P Lyritis
Journal:  Osteoporos Int       Date:  2015-03-05       Impact factor: 4.507

4.  Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.

Authors:  K Lippuner; H Johansson; F Borgström; J A Kanis; R Rizzoli
Journal:  Osteoporos Int       Date:  2012-01-06       Impact factor: 4.507

5.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

6.  Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks.

Authors:  N D Nguyen; S A Frost; J R Center; J A Eisman; T V Nguyen
Journal:  Osteoporos Int       Date:  2008-03-07       Impact factor: 4.507

7.  FRAX-based assessment and intervention thresholds--an exploration of thresholds in women aged 50 years and older in the UK.

Authors:  E McCloskey; J A Kanis; H Johansson; N Harvey; A Odén; A Cooper; C Cooper; R M Francis; D M Reid; D Marsh; P Selby; F Thompson; S Hewitt; J Compston
Journal:  Osteoporos Int       Date:  2015-06-16       Impact factor: 4.507

Review 8.  A systematic review of hip fracture incidence and probability of fracture worldwide.

Authors:  J A Kanis; A Odén; E V McCloskey; H Johansson; D A Wahl; C Cooper
Journal:  Osteoporos Int       Date:  2012-03-15       Impact factor: 4.507

9.  Lebanese guidelines for osteoporosis assessment and treatment: who to test? What measures to use? When to treat?

Authors:  Ghada El-Hajj Fuleihan; Rafic Baddoura; Hassane Awada; Jad Okais; Paul Rizk; Michael McClung
Journal:  J Clin Densitom       Date:  2005       Impact factor: 2.963

10.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

View more
  8 in total

1.  Effect of high dose vitamin D supplementation on indices of sarcopenia and obesity assessed by DXA among older adults: A randomized controlled trial.

Authors:  Jana Jabbour; Maya Rahme; Ziyad R Mahfoud; Ghada El-Hajj Fuleihan
Journal:  Endocrine       Date:  2022-01-14       Impact factor: 3.925

2.  Novel algorithm generating strategy to identify high fracture risk population using a hybrid intervention threshold.

Authors:  Chung-Yuan Hsu; Chih-Hsing Wu; Shan-Fu Yu; Yu-Jih Su; Wen-Chan Chiu; Ying-Chou Chen; Han-Ming Lai; Jia-Feng Chen; Chi-Hua Ko; Jung-Fu Chen; Tien-Tsai Cheng
Journal:  J Bone Miner Metab       Date:  2019-10-03       Impact factor: 2.626

Review 3.  Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Authors:  Joanna E M Sale; Matthew Gray; Daniel Mancuso; Taucha Inrig; Gilles Boire; Marie-Claude Beaulieu; Larry Funnell; Earl Bogoch
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

4.  Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.

Authors:  Deborah Mukherji; Bassem Youssef; Christelle Dagher; Albert El-Hajj; Rami Nasr; Fadi Geara; Danny Rabah; Saad Al Dousari; Rabih Said; Raja Ashou; Wassim Wazzan; Michel Jabbour; George Farha; Nibras Al Hamdani; Yousuf Al Hallaq; Hassan Ghazal; Haifa Dbouk; Bassel Bachir; Clement El Khoury; Ghazi Sakr; Hero K Hussain; Khaled Sayyid; Khaled Ibrahim; Mohammad Haidar; Nicolas Zouain; Nizar Bitar; Walid Alameh; Fadi Abbas; Sami Faddoul; Elie Nemer; Georges Assaf; Fadi Farhat; Muhammad Bulbul; Sally Temraz; Ali Shamseddine; Silke Gillessen; Aurelius Omlin; Raja Khauli
Journal:  World J Urol       Date:  2019-07-11       Impact factor: 4.226

Review 5.  The diversity of Fracture Risk Assessment Tool (FRAX)-based intervention thresholds in Asia.

Authors:  Sarath Lekamwasam
Journal:  Osteoporos Sarcopenia       Date:  2019-12-16

Review 6.  Nonpharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines.

Authors:  Roberto Coronado-Zarco; Andrea Olascoaga-Gómez de León; Araceli García-Lara; Jimena Quinzaños-Fresnedo; Tania Inés Nava-Bringas; Salvador Israel Macías-Hernández
Journal:  Osteoporos Sarcopenia       Date:  2019-10-04

7.  Intervention thresholds to identify postmenopausal women with high fracture risk: A single center study based on the Philippines FRAX model.

Authors:  Julie Li-Yu; Sarath Lekamwasam
Journal:  Osteoporos Sarcopenia       Date:  2021-09-20

8.  Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORD study.

Authors:  Nelly Ziade; Bernard El Khoury; Marouan Zoghbi; Georges Merheb; Ghada Abi Karam; Kamel Mroue'; Jamil Messaykeh
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.